Guanidinium-rich oligophosphotriesters transporter compounds and methods of making and using the same are provided. Also provided are pharmaceutical compositions that include the subject transporter compounds, where the transporter can be joined to a cargo of interest, and is formulated with a pharmaceutically acceptable excipient. Formulations may be provided in a unit dose, where the dose provides an amount of the compound effective to afford a desired therapeutic effect. Methods of using the subject transporter compounds to deliver a cargo moiety to a cell are provided, where the method can include contacting a target cell with the transporter compound. The subject methods can be performed in vitro or in vivo.

Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I):

##STR00001##

or a stereoisomer, tautomer or salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, L.sup.1, L.sup.2, L.sup.3, L.sup.4, M, m and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.

Phosphate-based polyallyl isocyanurate cross-linker compounds, polyalkenyl isocyanurate cross-linker compounds, and a flame-retardant resin are disclosed. The phosphate-based polyallyl isocyanurate compound can have allyl phosphate substituents with variable functional groups. The phosphate-based polyallyl isocyanurate compound can have three or six allyl phosphate substituents. The brominated polyalkenyl isocyanurate compound can have brominated alkene-terminated substituents. The brominated alkene-terminated substituents can have variable functional groups and variable chain lengths. Both the phosphate-based polyallyl isocyanurate compounds and the brominated polyalkenyl isocyanurate compounds can be cross-linkers for epoxide polymers, acrylate polymers, vinylbenzene-terminated poly(phenyleneoxide) polymers, etc. The phosphate-based polyallyl isocyanurate compounds and the brominated polyalkenyl isocyanurate compounds can also be flame-retardant. The flame-retardant resin can contain the phosphate-based polyallyl isocyanurate compounds or the brominated polyalkenyl isocyanurate compounds, and it can be incorporated into a printed circuit board laminate.

Disclosed are a near-infrared absorbing composition, an optical structure, and a camera module and an electronic device including the same. The near-infrared absorbing composition includes a copper complex represented by Chemical Formula 1.

##STR00001##

Definitions of Chemical Formula 1 are the same as described in the detailed description.

The invention provides compositions and methods for synthesis of phosphorylated organic compounds, including nucleoside triphosphates.

Polyolefin compositions comprising i) a polyolefin, ii) one or more phosphorus-containing benzofuranone compounds and iii) one or more hindered phenolic antioxidants are provided excellent protection against discoloration and enhanced thermal stability during melt processing as exhibited by improved retention of molecular weight and maintenance of polymer molecular architecture.

A polyethylene pipe comprising components A) and B), wherein component A) is a hindered amine light stabilizer containing a triazine residue, component B) is a natural or synthetic hydrotalcite and the weight ratio of component A) to component B) is 1:10 to 10:1.

Guanidinium-rich oligophosphotriesters transporter compounds and methods of making and using the same are provided. Also provided are pharmaceutical compositions that include the subject transporter compounds, where the transporter can be joined to a cargo of interest, and is formulated with a pharmaceutically acceptable excipient. Formulations may be provided in a unit dose, where the dose provides an amount of the compound effective to afford a desired therapeutic effect. Methods of using the subject transporter compounds to deliver a cargo moiety to a cell are provided, where the method can include contacting a target cell with the transporter compound. The subject methods can be performed in vitro or in vivo.

Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I):

##STR00001##

including stereoisomers, salts and tautomers thereof, wherein R.sup.1, R.sup.2, R.sup.3, L.sup.1, L.sup.2, L.sup.3, L.sup.4, L.sup.5, L.sup.6, M.sup.1, M.sup.2, A, q, w and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.

Phosphate-based linkers with tunable stability for intracellular delivery of drug conjugates are described. The phosphate-based linkers comprise a monophosphate, diphosphate, triphosphate, or tetraphosphate group (phosphate group) and a linker arm comprising a tuning element and optionally a spacer. A payload is covalently linked to the phosphate group at the distal end of the linker arm and the functional group at the proximal end of the linker arm is covalently linked to a cell-specific targeting ligand such as an antibody. These phosphate-based linkers have a differentiated and tunable stability in blood vs. an intracellular environment (e.g. lysosomal compartment).